“Wave of Chinese biotech deals builds as Harbour BioMed, Solstice sign US$1.2 billion pact ” — what this page in the network covers. China’s Harbour BioMed has struck a deal worth more than US$1.2 billion with a clinical-stage biotechnology company to develop and commercialise an antibod... China’s Harbour BioMed has struck a deal worth more than US$1.2 billion with a clinical-stage biotechnology company to develop and commercialise an antibody outside China, as the country’s novel drug makers increasingly secure not only upfront licensing fees but also long-term international partners Nova Global News curates publicly available headlines and summaries with source attribution.
Third-party article rights, trademarks, images, and publisher names belong to their respective owners; read the original article at the source for full context. Part of the Nova Ecosystem — the platform where AI apps, news, and tools are built and deployed. The full version stays on the original page, which this listing opens directly.